GlassScriptPhysician profile
Tiffany Tabiai
NPI 1477162204
$2,083.27
in general payments reported to CMS, 2019-2025
27 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $690 · 2023: $129 · 2024: $216 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259.85 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.54 | 2021-2022 | |
| Novo Nordisk INC | $189.35 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $146.13 | 2021-2022 | |
| Glaxosmithkline, LLC. | $134.90 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $134.71 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $93.36 | 2021-2024 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $92.42 | 2021-2024 | Mounjaro |
| Pfizer INC. | $87.54 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $85.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $77.97 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $68.66 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.90 | 2022 | |
| Astellas Pharma US INC | $64.45 | 2021-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $63.75 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $48.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $39.71 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.63 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.25 | 2021-2022 | |
| Dynavax Technologies Corporation | $28.13 | 2022-2025 | Heplisav-B |
| Supernus Pharmaceuticals, INC. | $27.27 | 2022-2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $20.47 | 2025 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $18.57 | 2025 | |
| Sumitomo Pharma America, INC. | $17.70 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $17.58 | 2024 | Thinprep 2000 Processor, Aptima |
| Exact Sciences Corporation | $16.84 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $10.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Tabiai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.